Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients

Completed

Conditions studied: Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised

In brief

The Sponsor hypothesize that Next-generation Sequencing (NGS) can identify fungal pathogens, is more accurate than other noninvasive options and can report fungal genomic load.

Key facts

Study ID

NCT03262584

Run by

Karius, Inc.

People needed

40

Starts

2017-05-17

Expected to finish

2018-09-28

Last updated by the study team

2019-06-17

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Prolonged FN (≥96 hours) despite broad-spectrum antibiotic therapy with anticipated delayed neutrophil recovery
• Any findings that trigger the primary team to consider new fungal infection in a given inpatient, such as abnormal imaging results, recrudescent fevers in the setting of neutropenia or characteristic skin rashes

You may not qualify if…

• Those without concern for fungal infection or those currently being treated for a presumed or documented fungal infection will not be recruited for this study

Where it is running

• Ann & Robert H. Lurie Children's Hospital of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.